FDG-PET in early AD diagnosis

Area of Science:

• Neurology
• Nuclear Medicine
• Diagnostic Imaging

Background:

• Alzheimer's disease (AD) diagnosis can be challenging, especially in early and prodromal stages.
• Distinguishing AD from other dementia types is crucial for appropriate patient management.
• FDG-PET offers insights into brain metabolism, a key indicator of neurodegenerative processes.

Purpose of the Study:

• To highlight the utility of FDG-PET in the early diagnosis and management of Alzheimer's disease.
• To emphasize the role of FDG-PET in differentiating AD from other dementias.
• To discuss the potential for increased clinical adoption of FDG-PET in AD diagnostics.

Main Methods:

• Utilizes Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) imaging.
• Involves interpretation of brain metabolic activity patterns.
• Focuses on identifying characteristic changes associated with Alzheimer's disease.

Main Results:

• FDG-PET is effective in identifying Alzheimer's disease in its prodromal and early dementia phases.
• The imaging technique aids in differentiating AD from other neurodegenerative conditions.
• FDG-PET allows for tracking disease progression over time.

Conclusions:

• FDG-PET is a valuable tool for early AD identification and monitoring.
• Growing availability of scans and trained readers, alongside increased clinician awareness, is expected to drive greater use of FDG-PET for AD diagnosis.
• The technique supports differential diagnosis and disease staging in dementia patients.